Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis. - Freedland, Stephen J.; Gleave, Martin; De Giorgi, Ugo; Rannikko, Antti; Sridharan, Swetha; Brasso, Klaus; Woo, Henry H.; Gómez Caamaño, Antonio; Nordquist, Luke; Tang, Yiyun; Croitoru, Ruslan; Rosales, Matt; et al. (Journal of Clinical Oncology)